Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 4 25 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 10.
Head-to-head clinical analysis: AMINOSYN 4 25 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 10.
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 10%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 4.25% w/ Dextrose 25% provides amino acids for protein synthesis and dextrose as a caloric source, supporting nitrogen balance and energy requirements in parenteral nutrition.
Amino acids provide substrates for protein synthesis and nitrogen balance maintenance in patients unable to tolerate adequate oral/enteral intake.
Adults: 1-3 L/day intravenously through central line. Infusion rate initially 50-100 mL/hour, titrate to achieve protein and calorie requirements.
Intravenous infusion: 500 mL to 1 L of 10% solution (50-100 g amino acids) per day, administered at a rate not exceeding 100 mL/h. Typical initial dose: 0.8-1.5 g/kg/day of amino acids, adjusted based on metabolic needs and tolerance.
None Documented
None Documented
Amino acids: 10-30 min (rapid distribution). Dextrose: glucose half-life ~1.5-2 h in euglycemia; prolonged in renal impairment. Clinically, continuous infusion maintains steady state without significant accumulation.
Variable depending on metabolic state; for individual amino acids, half-lives range from 10 to 100 minutes. In renal impairment, accumulation can occur. No single terminal half-life for the mixture.
Amino acids are metabolized; nitrogen waste is excreted renally as urea. Dextrose is metabolized to CO2 and water. Renal excretion accounts for >95% of nitrogen elimination. Minimal biliary/fecal elimination.
Primarily renal as amino acids and metabolites; >90% of infused amino acids are reabsorbed by proximal tubules, with less than 10% excreted unchanged in urine. Biliary/fecal excretion negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution